Impact BioMedical Inc(IBO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.24 | Insider Own | 7.36% | Shs Outstand | 107.8M | Perf Week | 5.56% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.14% | Shs Float | 99.9M | Perf Month | -30.02% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 0.28% | Short Float | 0.03% | Perf Quarter | -31.41% |
| Income | 0.00B | P/S | 811.55 | EPS this Y | - | Inst Trans | 0.19% | Short Ratio | 1.7 | Perf Half Y | -54.17% |
| Sales | 0.00B | P/B | 3.02 | EPS next 5Y | - | ROA | 4.41% | Short Interest | 0.03M | Perf YTD | -40.37% |
| Book/sh | 1.26 | P/C | 3246.2 | EPS past 3/5Y | 15.09% -48.52% | ROE | 371.29% | 52W High | -63.72% ($10.47) | Perf Year | -42.75% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 7.33% | 52W Low | 56.38% ($2.43) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 97% | Gross Margin | -4377.14% | Volatility(W/M) | 19.57% 18.51% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 892.55 | Sales Y/Y TTM | 400% | Oper. Margin | -14562.86% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.13 | EPS Q/Q | 99.45% | Profit Margin | 2254.29% | RSI (14) | 43.44 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.16 | Sales Q/Q | -57.14% | SMA20 | -0.39% ($3.81) | Beta | 2.76 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -26.38% ($5.16) | Rel Volume | 0.99 | Prev Close | $3.87 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -39.31% ($6.26) | Avg Volume(3M) | 0.02M | Price | $3.8 |
| IPO | 2024/9/16 | Option/Short | No/Yes | Trades | 380 | Volume | 15,274 | Change | -1.81% |
A U.S. intellectual property (IP)-drivn biotech company that targets cancer, infectious diseases, and metabolic disorders through plant-based functional materials and a novel drug platform. Leveraging its proprietary antimicrobial technology and small-molecule compounds, the company is pursuing commercialization through global partnerships.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded about as much as usual. That is 99% of its average volume.
IBO has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $81,155. Peers typically go for $1,010.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
ITOT iShares Core S&P Total U.S. Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #441 of 595 in the industry
Based on market cap of $32M.
NNVC#438 NanoViricides Inc $34M PER - 
ALDX#439 Aldeyra Therapeutics Inc $34M PER - 
IRLA#440 IRulya Therapeutics Inc $34M PER - IBO#441 Impact BioMedical Inc $32M PER - 
ACET#442 Adicet Bio Inc $32M PER - 
FAQ
What kind of company is IBO?
IBO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IBO?
The market cap of IBO is approximately $32M, ranking 5,032 within its sector.
What is the 52-week high and low for IBO?
IBO has recorded a 52-week high of $10.47 and a low of $2.43.
